Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “GD2 Antibody”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 9 of 0 results

Testing effectiveness (Phase 2)Looking for participantsNCT07537400
What this trial is testing

Patients Between the Ages of 12 Months to 21 Years With Newly-Diagnosed High-Risk Neuroblastoma Will Receive Children's Oncology Group (COG) Type Recommended Therapy With the Addition of Naxitamab and Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) to Induction Cycles 1-5

Who this might be right for
High-Risk Neuroblastoma
Shaare Zedek Medical Center 10
Early research (Phase 1)Study completedNCT00005576
What this trial is testing

Monoclonal Antibody Therapy With Sargramostim and Interleukin-2 in Treating Children With Neuroblastoma

Who this might be right for
Disseminated NeuroblastomaRecurrent NeuroblastomaRegional Neuroblastoma
National Cancer Institute (NCI) 6
Early research (Phase 1)Study completedNCT00003023
What this trial is testing

Monoclonal Antibody A1G4 Plus BCG in Treating Patients With Cancer

Who this might be right for
NeuroblastomaSarcoma
Memorial Sloan Kettering Cancer Center 24
Testing effectiveness (Phase 2)Ended earlyNCT04750239
What this trial is testing

Safety and Clinical Activity of Nivatrotamab in Relapsed/Recurrent Metastatic Small-cell Lung Cancer

Who this might be right for
SCLC
Y-mAbs Therapeutics 3
Testing effectiveness (Phase 2)Study completedNCT00445965
What this trial is testing

Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer

Who this might be right for
Brain and Central Nervous System TumorsIntraocular MelanomaLung Cancer+7 more
Memorial Sloan Kettering Cancer Center 78
Testing effectiveness (Phase 2)Study completedNCT00002458
What this trial is testing

Monoclonal Antibody Therapy in Treating Children With Metastatic Neuroblastoma in Second Remission

Who this might be right for
Neuroblastoma
Memorial Sloan Kettering Cancer Center
Testing effectiveness (Phase 2)Study completedNCT01857934
What this trial is testing

Therapy for Children With Advanced Stage Neuroblastoma

Who this might be right for
Neuroblastoma
St. Jude Children's Research Hospital 153
Early research (Phase 1)Study completedNCT01662804
What this trial is testing

Humanized 3F8 Monoclonal Antibody (Hu3F8) When Combined With Interleukin-2 in Patients With High-Risk Neuroblastoma and GD2-positive Solid Tumors

Who this might be right for
Neuroblastoma
Memorial Sloan Kettering Cancer Center 14
Not applicableActive Not RecruitingNCT06480526
What this trial is testing

Feasibility of Screening for Early Late Effects of Contemporary Therapy in High-Risk Neuroblastoma Survivors

Who this might be right for
High-risk Neuroblastoma
St. Jude Children's Research Hospital 34